CBP Rulings
Index coverage and update dates
- Indexed
- 6,578 rulings
- NY rulings from
- Nov 2024
- Newest here
- Nov 12, 2026
- Newest on CBP
- Nov 13, 2026
- Customs Bulletin through
- Nov 18, 2026
- Last sync with CBP
- 1 hour ago
- NY N347096Apr 2, 2025
The tariff classification of Aceclidine Ophthalmic Solution in dosage form, from the United States
In your letter dated March 25, 2025, you requested a tariff classification ruling. The country of origin determination of this product was separately addressed under NY N343405 dated November 7, 2024. Aceclidine Ophthalmic Solution is a medicinal preparation containing Aceclidine Hydrochloride, a parasympathomimetic miotic agent, as the active ingredient. Currently it is under development for the treatment of presbyopia in adult patients, an age-related eye condition that makes it difficult to focus on nearby objects.
- NY N346320Mar 21, 2025
The tariff classification of Dorzolamide Hydrochloride (HCL)/Timolol Maleate Ophthalmic drops in dosage form, from India
In your letter dated February 27, 2025, you requested a tariff classification ruling. Dorzolamide HCL/Timolol Maleate Ophthalmic drops, imported in 10 mL, is a combination medication containing, Dorzolamide Hydrochloride (a carbonic anhydrase inhibitor) and Timolol Maleate (a beta-adrenergic receptor blocking agent), as the active ingredients. It is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers.
- NY N345194Feb 6, 2025
The tariff classification and country of origin of Formoterol Soln Neb (Formoterol Fumarate Inhalation Solution)
In your letter dated January 15, 2025, on behalf of your client, Dr. Reddy’s Laboratories, Incorporated, you requested a tariff classification and country of origin determination ruling. Formoterol Soln Neb, imported in 20 mcg /2 mL vials, is a medicinal preparation containing Formoterol Fumarate Dihydrate, a long-acting beta agonists (LABAs), as the active ingredient. It is indicated for the treatment of bronchoconstriction in patients with Chronic Obstructive Pulmonary Disease (COPD).
Source: rulings.cbp.gov (CROSS). This index holds New York rulings issued since Nov 2024 and the Headquarters rulings they cite. It is not the full CROSS database of 222,467 rulings, and it does not hold every Headquarters ruling. New rulings usually appear here within a few days of CBP publishing them; a ruling published long after its number was assigned can take several weeks. Revoked, modified and proposed marks come from the weekly Customs Bulletin, where CBP publishes most such actions under 19 U.S.C. 1625(c), read here from the Nov 2024 issues onward, and from the subjects of indexed Headquarters rulings. A revocation is marked from the date it takes effect. The absence of a mark is not confirmation that a ruling is still in effect. A ruling letter is binding on CBP only for the particular transaction or issue it describes (19 CFR 177.9). Confirm the text and status on CROSS before relying on a ruling. Not legal advice.